NCT00673075

The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease

Efficacy and Tolerability of Nebivolol Compared With Carvedilol in Patients With Coronary Artery Disease and Stage I or II Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Forest Laboratories · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery disease.

Conditions

• Hypertension
• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Nebivolol	Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
DRUG	Carvedilol	Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily

Timeline

• Start date: 2008-05-01
• Primary completion: 2009-09-01
• First posted: 2008-05-07
• Last updated: 2010-09-28
• Results posted: 2010-09-28

Locations

34 sites across 1 country: United States